OBJECTIVE: We report on the uptake and psychological impact of p16-Leiden genetic testing to contribute to a greater understanding of counseling melanoma families. METHODS: Within a defined research setting, genetic counseling and testing were offered to members of p16-Leiden-positive melanoma pedigrees, at risk of carrying a gene defect associated with an increased risk of melanoma and pancreatic cancer. RESULTS: One hundred and eighty-four individuals sought counseling, of which 141 (77%) opted for genetic testing. Uptake of genetic counseling and testing, and psychological motivation was evaluated in 94 (57%) individuals. Higher pre-test risk of carrying the mutation and older age proved significantly predictive for counseling uptake. Age was predictive for test acceptance, whereas fearful test expectancies predicted test decline. Counselees had lower distress levels than those reported in other oncogenetic testing settings. CONCLUSION: We are the first to report on genetic testing for familial melanoma. Following the first counseling session, we found a relatively high uptake rate for p16-Leiden testing and no clinically worrisome levels of distress.
OBJECTIVE: We report on the uptake and psychological impact of p16-Leiden genetic testing to contribute to a greater understanding of counseling melanoma families. METHODS: Within a defined research setting, genetic counseling and testing were offered to members of p16-Leiden-positive melanoma pedigrees, at risk of carrying a gene defect associated with an increased risk of melanoma and pancreatic cancer. RESULTS: One hundred and eighty-four individuals sought counseling, of which 141 (77%) opted for genetic testing. Uptake of genetic counseling and testing, and psychological motivation was evaluated in 94 (57%) individuals. Higher pre-test risk of carrying the mutation and older age proved significantly predictive for counseling uptake. Age was predictive for test acceptance, whereas fearful test expectancies predicted test decline. Counselees had lower distress levels than those reported in other oncogenetic testing settings. CONCLUSION: We are the first to report on genetic testing for familial melanoma. Following the first counseling session, we found a relatively high uptake rate for p16-Leiden testing and no clinically worrisome levels of distress.
Authors: J Scott Roberts; David I Shalowitz; Kurt D Christensen; Jessica N Everett; Scott Y H Kim; Leon Raskin; Stephen B Gruber Journal: J Empir Res Hum Res Ethics Date: 2010-09 Impact factor: 1.742
Authors: Xuan Zhu; Emma R Leof; Kari G Rabe; Jennifer B McCormick; Gloria M Petersen; Carmen Radecki Breitkopf Journal: Public Health Genomics Date: 2019-04-18 Impact factor: 2.000
Authors: Kurt D Christensen; J Scott Roberts; David I Shalowitz; Jessica N Everett; Scott Y H Kim; Leon Raskin; Stephen B Gruber Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-02-09 Impact factor: 4.254
Authors: Ellen Wright Clayton; Laurence B McCullough; Leslie G Biesecker; Steven Joffe; Lainie Friedman Ross; Susan M Wolf Journal: Am J Bioeth Date: 2014 Impact factor: 11.229
Authors: Donald W Hadley; Sato Ashida; Jean F Jenkins; Jean C Martin; Kathleen A Calzone; Natalia R Kuhn; Colleen M McBride; Ilan R Kirsch; Laura M Koehly Journal: Genet Med Date: 2010-12 Impact factor: 8.822